86625-25-4

Usage

Uses

Used in Pharmaceutical Industry:
METHYL 5-HYDROXY-PYRAZOLE-3-CARBOXYLATE is used as a key intermediate in the synthesis of various pharmaceuticals for its ability to contribute to the development of new drugs with improved efficacy and safety profiles.
Used in Agrochemical Industry:
In the agrochemical sector, METHYL 5-HYDROXY-PYRAZOLE-3-CARBOXYLATE is utilized as a component in the creation of agrochemicals, potentially enhancing crop protection and yield through its incorporation into novel compounds.
Used in Fine Chemicals Industry:
METHYL 5-HYDROXY-PYRAZOLE-3-CARBOXYLATE is employed as a building block in the synthesis of fine chemicals, where its unique structure and properties are leveraged to produce high-quality specialty chemicals for various applications.
Used in Research and Development:
METHYL 5-HYDROXY-PYRAZOLE-3-CARBOXYLATE is used as a research compound for exploring its unique chemical properties and potential applications in new areas of chemistry and biology, including drug discovery and medicinal chemistry.
Used in Medicinal Chemistry and Drug Discovery:
METHYL 5-HYDROXY-PYRAZOLE-3-CARBOXYLATE is utilized as a modulator of biological targets, playing a crucial role in the development of new therapeutic agents with novel mechanisms of action.

InChI:InChI=1/C5H6N2O3/c1-10-5(9)3-2-4(8)7-6-3/h2H,1H3,(H2,6,7,8)

Upstream product

• 25007-54-9 Dimethyl 2-oxosuccinate 
• 762-42-5 dimethyl acetylenedicarboxylate 
• 67-56-1 methanol 
• 64-19-7 acetic acid 

Downstream Products

• 762-42-5 dimethyl acetylenedicarboxylate 
• 52867-42-2 5-hydroxy-2-methyl-2H-pyrazole-3-carboxylic acid methyl ester 
• 1254966-07-8 5-(5-methyl-3-phenyl-isoxazol-4-ylmethoxy)-2H-pyrazole-3-carboxylic acid methyl ester 
• 1254966-31-8 5-[5-((1S,2R)-1,2-dihydroxy-2-phenyl-ethyl)-3-(4-fluoro-phenyl)-isoxazol-4-ylmethoxy]-2-methyl-2H-pyrazole-3-carboxylic acid methyl ester 
• 1254966-38-5 5-[3-butyl-5-(1,2-dihydroxy-2-phenyl-ethyl)-isoxazol-4-ylmethoxy]-2-methyl-2H-pyrazole-3-carboxylic acid methyl ester 
• 1254966-32-9 5-[3-(4-fluoro-phenyl)-5-hydroxymethyl-isoxazol-4-ylmethoxy]-2-methyl-2H-pyrazole-3-carboxylic acid methyl ester 
• 1254966-30-7 5-[3-(4-fluoro-phenyl)-5-formyl-isoxazol-4-ylmethoxy]-2-methyl-2H-pyrazole-3-carboxylic acid methyl ester 
• 1254966-28-3 2-methyl-5-[5-methyl-3-(tetrahydro-pyran-4-yl)-isoxazol-4-ylmethoxy]-2H-pyrazole-3-carboxylic acid methyl ester 
• 1254966-20-5 2-methyl-5-(5-methyl-3-phenyl-isoxazol-4-ylmethoxy)-2H-pyrazole-3-carboxylic acid methyl ester 
• 926296-28-8 methyl 1-[2-chloro-4-(trifluoromethyl)benzyl]-3-(methoxymethoxy)-1H-pyrazole-5-carboxylate 
• 888738-72-5 methyl 1-benzyl-3-isopropoxy-1H-pyrazole-5-carboxylate 
• 888741-09-1 methyl 1-benzyl-3-(benzyloxy)-1H-pyrazole-5-carboxylate 
• 52867-49-9 1-benzyl-3-hydroxy-5-methoxycarbonyl-1H-pyrazole 

Relevant academic research and scientific papers

NOVEL HETEROCYCLIC COMPOUNDS AS BET INHIBITORS

Provided are heterocyclic compounds of formula (I) as bromodomain and extraterminal (BET) inhibitors, pharmaceutical compositions comprising the compounds, their synthesis and their use for treating diseases and conditions wherein inhibition of one or more BET bromodomains provides a benefit.

2-OXA-5-AZABICYCLO[2.2.1]HEPTAN-3-YL DERIVATIVES

The present invention relates to compounds of formula (I), wherein L is a bond, -C(O)NH-, -NHC(O)-, -CH2NHC(O)-, CH2C(O)NH-, -CH2NH-, -NH- or -NHC(O)NH-; R1 is hydrogen, lower alkyl, halogen, lower alkoxy-alkyl, lower alko

MORPHOLIN-PYRIDINE DERIVATIVES

The present invention relates to compounds of formula (I) wherein X is CR or N; R is hydrogen, halogen or lower alkyl; L is a bond, -C(O)- or -C(O)NH-; Ar is phenyl or a five or six membered heteroaryl group, containing one or two N atoms; R1 i

A new class of non-thiazolidinedione, non-carboxylic-acid-based highly selective peroxisome proliferator-activated receptor (PPAR) γ agonists: Design and synthesis of benzylpyrazole acylsulfonamides

Herein, we describe the design, synthesis, and structure-activity relationships of novel benzylpyrazole acylsulfonamides as non-thiazolidinedione (TZD), non-carboxylic-acid-based peroxisome proliferator-activated receptor (PPAR) γ agonists. Docking model analysis of in-house weak agonist 2 bound to the reported PPARγ ligand binding domain suggested that modification of the carboxylic acid of 2 would help strengthen the interaction of 2 with the TZD pocket and afford non-carboxylic-acid-based agonists. In this study, we used an acylsulfonamide group as the ring-opening analog of TZD as an isosteric replacement of carboxylic acid moiety of 2; further, preliminary modification of the terminal alkyl chain on the sulfonyl group gave the lead compound 3c. Subsequent optimization of the resulting compound gave the potent agonists 25c, 30b, and 30c with high metabolic stability and significant antidiabetic activity. Further, we have described the difference in binding mode of the carboxylic-acid-based agonist 1 and acylsulfonamide 3d.

ISOXAZOLE-PYRAZOLE DERIVATIVES

The present invention is concerned with isoxazole-pyrazole derivatives of formula I, having affinity and selectivity for GABA A α5 receptor, their manufacture, pharmaceutical compositions containing them and their use as medicaments. The active compounds of the present invention are useful as cognitive enhancer or for the therapeutic and/or prophylactic treatment of cognitive disorders like Alzheimer's disease.

PYRAZOLE DERIVATIVE, INTERMEDIATE THEREFOR, PROCESSES FOR PRODUCING THESE, AND HERBICIDE CONTAINING THESE AS ACTIVE INGREDIENT

The present invention provides a pyrazole derivative of the general formula (1), which has an excellent efficacy as an active component for a herbicide, an intermediate for the production thereof, processes for the production thereof, and a herbicide cont